The U.S. premenstrual syndrome treatment market reached USD 520.0 Million in 2024. IMARC Group forecasts it will grow to USD 733.7 Million by 2033, at a CAGR of 3.71% from 2025 to 2033, driven by increasing awareness, improved healthcare access, and rising demand for effective symptom management therapies. https://www.imarcgroup.com/united-states-premenstrual-syndrome-treatment-market